Because of VRE's shift to a strictly residential portfolio the company is likely to struggle. On top of that the stock is overvalued compared to its peers.Read full newsRead More
Risk in banks is heightening, the Federal Reserve is tightening, and the market looks frightening.Read full newsRead More
Warren Buffett has always been greedy when investors are fearful. Mr. Buffett's dealmaking during troubled times involves a waiting fee. Click for our picks.Read full newsRead More
The following slide deck was published by OmniAb, Inc.Read full newsRead More
OmniAb, Inc. (NASDAQ:NASDAQ:OABI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsKurt Gustafson - CFOMatt Foehr - President and CEOConference Call...Read full newsRead More
Straumann (SAUHF) is a quality business and is a world leader in its domain. Check out why I'm neutral on Straumann stock.Read full newsRead More
Cantaloupe relies on non-financing means of generating cash which is not sustainable. Read why I don't regard CTLP stock as a buy.Read full newsRead More
Devon Energy announced lower-than-expected adjusted earnings of $1.66 from $1.39 a year ago. Read more to see why DVN stock is a Hold.Read full newsRead More
Charles Schwab has seen an acceleration of money inflows which came in at twice the rate as the FY 2022 weekly average. Click here to read why I rate SCHW stock a Buy?Read full newsRead More
Alpine Income's dividend yield of 6.5% (~75% implied FFO payout for 2023) is extremely safe. Read why I'm bullish on PINE stock.Read full newsRead More
Lockheed Martin has rallied over the past two years, though not as much as you might expect given global geopolitical developments. Read more to see why LMT stock is a Buy.Read full newsRead More
Forty-nine small-cap energy producers are ranked on relative quality using a matrix with factors including, valuation, profitability, FCF, and debt. Click here to find out.Read full newsRead More
In October I showcased my full portfolio. Read more to see an update on how my portfolio developed.Read full newsRead More
Cytokinetics has developed aficamten and has received FDA orphan drug designation and Breakthrough Therapy Designation. See why I'm bearish on CYTK stock.Read full newsRead More
Amazon has been operating for almost 30 years, and still seems content to sacrifice short-term profit for long-term growth. Read more to see why AMZN stock is a HoldRead full newsRead More
Voyager is a preclinical company with multibillion dollar big pharma deals. Read why I will stay on the sidelines with VYGR stock.Read full newsRead More
Imperial Petroleum is a new energy shipping company resulting from a spinoff. Read more to see why we rate the preferred, IMPPP stock, a Buy.Read full newsRead More
Vericel Corporation is an innovative leader with a strong pipeline of FDA-approved and investigational products that address unmet medical needs. Click here to read more.Read full newsRead More
Nano Dimension attained its highest yearly revenues recorded in their history in Q4 2022. Check out why I rate NNDM stock a hold.Read full newsRead More
Real estate equities were again among the leaders this week. Click here to read the full report.Read full newsRead More